© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Posted 7th March 2016

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health

Avant Diagnostics, Inc, a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acqu

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Image

Avant Diagnostics, Inc., a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated, adding key CLIA laboratory and intellectual property capabilities to Avant’s previously announced letter of intent to merge with Amarantus Diagnostics (collectively, the “Transactions”).

THI currently generates over $1.5M in services revenue from some of the world’s leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue. The companies will be holding a conference call to discuss the business combination today at 4:30 PM ET. To access the conference call please dial 215-383-1625 or toll free 800-356-8278; access code 135394.

Under the terms of the letter of intent, Avant shall issue to THI 25 million shares of its common stock upon the closing. Amarantus BioScience has provided a convertible note of $400,000 to THI to facilitate the transaction that will be assumed by Avant upon closing of the transactions. As previously disclosed, Avant plans to issue 80 million shares of its common stock to Amarantus Biosciences upon completion of its merger with Amarantus Diagnostics. The Transactions are expected to close in the first half of 2016, and are subject to customary closing conditions.

Gerald E. Commissiong, President & CEO of Amarantus said:

“THI is a leader in the area of signal transduction biology, where they have been able to attract an A-list of pharmaceutical customers collaborating with the company to evaluate the therapeutic benefit and potential of their drug candidates using THI’s proprietary assays.

“In addition, THI has a CLIA lab where Amarantus’ Diagnostics has established operations over the course of the first quarter that will allow for CLIA validation and commercial launch of the combined company’s suite of high-value, proprietary diagnostics in the areas of oncology and neurology. THI’s sales channel into the pharmaceutical industry will provide important leverage for the combined company to market the LymPro Test® for Alzheimer’s disease. We could not have picked a better partner to bring Avant and Amarantus’ Diagnostics leading-edge intellectual property in diagnostics and biomarkers to the market.”

Gregg Linn, President & CEO of Avant Diagnostics added:

“Key to the business case for the merged company is THI’s impressive pharma services revenue base and sales channel in the area of cell signaling biology. In addition to this, THI’s CLIA laboratory provides the combined company with the infrastructure to launch OvaDx®, MSPrecise® and LymPro Test in a regulatory compliant environment that has been vetted by some of the world’s top pharmaceutical companies. THI’s laboratory meets the highest quality standards under CLIA/CAP which should give both our pharmaceutical and commercial customers great confidence in the information generated in THI’s laboratory.”

THI’s core business is centred on providing pharmaceutical and biotechnical companies access to its technology for quantitatively measuring the activation status of key proteins and signal transduction pathways that are dysregulated in multiple disease processes via its Reverse-phase Protein Array (RPPA) platform. THI is experienced in running CAP-accredited assays in its CLIA laboratory for predicting response to therapies in difficult to treat cancers.  THI believes that, while genomic approaches may identify potential activating mutations in diseased tissues, measuring the actual activation status of the protein drug targets and the signal transduction pathways that they regulate, provides physicians with much-needed evidence that a particular therapeutic strategy can provide benefits to the patient.  THI has launched tests, TheraLink® Assays, for guiding therapeutic decisions in breast and colorectal cancer. The post-merger Avant Diagnostics will further build on its recognized scientific expertise in the area of cell cycle biology to increase its pharma services revenues and provide therapy guiding diagnostics in difficult to treat conditions.

Glenn Hoke, PhD, Chief Executive Officer of THI added:

“After an extensive evaluation of the diagnostics market, we believe that we have found the best potential partners in Avant and Amarantus. It is clear that we will be expanding our CLIA offerings with much needed tests such as OvaDx in cancer and MSPrecise in neurology, while also providing significant additional pharma services business development opportunities with the LymPro Test. With platforms in microarray proteomics, ELISA, flow cytometry and ‘next-gen’ sequencing, the combined company’s capabilities will allow it to add cross-platform diagnostics as we grow into the future.”

 

 

Categories: Innovation, M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
Jet Environmental and Jet AHU Acquired by Wozair Ltd
M&A
14/07/2016Jet Environmental and Jet AHU Acquired by Wozair Ltd

Jet Environmental Systems Ltd, the provider of temperature control solutions for industrial and commercial buildings, and its sister company Jet AHU Ltd, which supplies and installs air handling units, have been acquired by Wozair Ltd.

Read Full PostRead - Eye Icon
Everything You Need to Know About Virtual Data Rooms
Innovation
04/03/2022Everything You Need to Know About Virtual Data Rooms

In the current world, digital companies are becoming more prominent in the business sphere. Resulting in an increase in data management by businesses, though with the increase in data responsibility is needed for those businesses to protect and manage that dat

Read Full PostRead - Eye Icon
TJP Advised TTTech Computer Technology AG on Capital Increase of €50 million
Finance
20/04/2015TJP Advised TTTech Computer Technology AG on Capital Increase of €50 million

TJP advised TTTech Computer Technology AG on capital increase of €50 million resulting in Infineon and GE Ventures investing in TTTech Computertechnik AG, the technology leader in robust networked safety controls.

Read Full PostRead - Eye Icon
Why Sales Teams Need Better Visibility Into the Calls That Drive Revenue
Strategy
15/09/2026Why Sales Teams Need Better Visibility Into the Calls That Drive Revenue

Why Sales Teams Need Better Visibility Into the Calls That Drive Revenue Sales teams generate valuable information during calls. Yet when the data is scattered, assumptions rather than facts influence training choices, marketing campaigns, and revenue projecti

Read Full PostRead - Eye Icon
Changing Perception On Collecting Information
Innovation
28/01/2020Changing Perception On Collecting Information

Conventionally, data mining in biomedicine in the ‘omics’ era refers to a bioinformatics approach that combines key concepts of biology with advanced computer tools or statistical methods that are primarily used to discover, select and prioritize targets.

Read Full PostRead - Eye Icon
5 Innovative and Advantageous Improvements To Your Business Model You Cannot Afford To Ignore
Innovation
09/07/20215 Innovative and Advantageous Improvements To Your Business Model You Cannot Afford To Ignore

Whatever industry your company specializes in, it's important to examine your business model, identify areas that require improvement and implement those changes as soon as possible.

Read Full PostRead - Eye Icon
Building the Future: What Today’s Tech Candidates Really Look for in Companies
Innovation
09/10/2023Building the Future: What Today’s Tech Candidates Really Look for in Companies

The technology sector is renowned for its rapid pace of innovation and dynamic work environments. Consequently, tech candidates are often discerning about the companies they aim to join, seeking opportunities that not only utilise their skills but also foster

Read Full PostRead - Eye Icon
Wind Turbine Composites Material Market Worth $5.5 Billion by 2020
Finance
06/03/2015Wind Turbine Composites Material Market Worth $5.5 Billion by 2020

New report defines and segments the global composite market for wind turbine with an analysis and forecast of its global volume and value.

Read Full PostRead - Eye Icon
CEO of the Year, Austria
Leadership
02/02/2016CEO of the Year, Austria

Vienna International Hotelmanagement AG looks back on more than 26 years of success, during which time it has focused on building and expanding its portfolio of hotels in the 3- to 5-star segment.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow